Highest-materiality recent filing
Hims & Hers Q2 revenue up 38% to $753M; raises FY26 guidance to $3.1-3.3B
Q2 revenue $753.2M, +38% YoY; subscribers 2.89M, +19% YoY.
Hims & Hers enters $400M receivables purchase facility with JPMorgan, 364-day term
Receivables Purchase Agreement allows sale of eligible receivables up to $400M outstanding.
Hims & Hers completes acquisition of Eucalyptus; reaffirms 2030 targets of $6.5B revenue
Acquisition closed, making Hims & Hers the world's largest consumer health platform.
Hims & Hers issues $402.5M of 0% convertible notes due 2032; enters capped calls
Issued $402.5M aggregate principal of 0.00% Convertible Senior Notes due June 1, 2032.
Hims & Hers prices $350M 0.00% convertible notes due 2032; funds Eucalyptus acquisition & AI
Offering upsized from $300M to $350M; initial purchasers can buy additional $52.5M.
Hims & Hers Q1 net loss $92.1M; revenue $608M (+4% YoY); raises FY2026 guidance to $2.8B-$3.0B
Revenue $608.1M (+4% YoY); net loss $92.1M vs net income $49.5M in Q1 2025.
Hims & Hers partners with Novo Nordisk, shifts US weight loss strategy to FDA-approved GLP-1s
Collaboration with Novo Nordisk to offer Ozempic and Wegovy on platform starting March 2026.
Hims & Hers FY2025 revenue up 59% to $2.35B, adj. EBITDA $318M; guides FY2026 rev $2.7-2.9B
Revenue $2.35B (+59% YoY); net income $128M; adj. EBITDA $318M vs $177M prior year.
Hims & Hers acquires Eucalyptus for up to $1.15B, expanding globally
Transaction valued up to $1.15B: ~$240M cash upfront, ~$710M deferred over 18 months, up to ~$200M earnouts.
Hims & Hers Health authorizes new $250M share repurchase program; prior $100M fully used
New $250M share repurchase program authorized by Board on Nov 13, 2025, expiring Nov 11, 2028.
Hims & Hers Q3 revenue $599M (+49% YoY), Adj. EBITDA $78.4M; narrows FY25 guidance
Q3 revenue $599M (+49% YoY), net income $15.8M (prior-year $75.6M included $60.8M tax benefit)
Hims & Hers signs 15-year lease for 352,012 sq ft Ohio facility
Lease for 352,012 sq ft in New Albany, OH, for office, R&D, lab, manufacturing, and pharmaceutical dispensing.
Hims & Hers Q2 rev $545M (+73%), net income $42.5M, reaffirms FY25
Revenue $544.8M (+73% YoY); net income $42.5M (vs $13.3M); Adj EBITDA $82.2M (vs $39.3M).
$1.0B aggregate principal of 0.00% Convertible Senior Notes due 2030 issued May 13, 2025.
Hims & Hers prices $870M 0.00% convertible notes due 2030 for global expansion and AI investment
Initial $450M offering upsized to $870M; initial purchasers option for additional $130M.
Hims & Hers Q1 revenue $586M (+111% YoY), net income $49.5M, raises EBITDA guidance
Revenue $586M (+111% YoY); net income $49.5M (up 345% YoY); Adj. EBITDA $91.1M (up 182% YoY).
Hims & Hers FY2024 revenue $1.48B (+69% YoY); net income $126M vs loss; guides FY2025 rev $2.3-2.4B
Revenue $1.48B for FY2024, up 69% YoY; Q4 revenue $481M, up 95% YoY.
Hims & Hers Q3 rev $401.6M (+77% YoY), net income $75.6M, raises FY guidance
Q3 2024: Revenue $401.6M (+77% YoY), net income $75.6M (vs -$7.6M), Adj EBITDA $51.1M.
Hims & Hers Q2 revenue $315.6M (+52% YoY), turns profitable; raises FY outlook
Revenue $315.6M, up 52% YoY; subscribers 1.9M (+43% YoY).
Hims & Hers Q1 2024 revenue $278.2M (+46% YoY), net income $11.1M, raises FY guidance
Revenue $278.2M, up 46% YoY; net income $11.1M vs loss of $10.1M a year ago.
Hims & Hers FY2023 revenue $872M (+65% YoY); Q4 net income $1.2M; guides FY2024 rev $1.17-1.20B
FY2023 revenue $872.0M, up 65% YoY; net loss improved to $(23.5)M from $(65.7)M.
Hims & Hers Q3 revenue $226.7M (+57% YoY), adjusted EBITDA $12.3M; raises FY outlook
Revenue of $226.7M for Q3 2023, up 57% YoY from $144.8M; net loss narrowed to $7.6M from $18.8M.
Hims & Hers Q2 revenue up 83% to $207.9M; raises FY 2023 guidance
Revenue $207.9M, up 83% YoY; net loss narrowed to $7.2M from $19.7M.
Hims & Hers Q1 revenue up 88% to $190.8M; raises FY2023 guidance
Revenue $190.8M (+88% YoY); net loss narrowed to $10.1M from $16.3M; adj. EBITDA $6.1M vs -$6.1M.
Hims & Hers Q4 revenue $167.2M (+97% YoY); achieves first positive adjusted EBITDA of $3.9M
Q4 revenue $167.2M, up 97% YoY; full year revenue $526.9M, up 94% YoY.
Revenue of $144.8M, up 95% YoY; net loss $(18.8)M vs $(15.9)M a year ago.
Hims & Hers Q2 revenue $113.6M (+87% YoY); raises FY22 revenue guidance to $470-485M
Revenue of $113.6M, up 87% YoY; net loss $(19.7M) vs $(9.2M) prior year.
Hims & Hers Q1 revenue $101.3M (+94% YoY); raises FY2022 guidance to $410-425M
Revenue $101.3M, up 94% YoY; net loss improved to $(16.3)M from $(51.4)M.
Hims & Hers Q4 revenue $84.7M (+104% YoY); FY2021 revenue $271.9M; guides FY2022 rev $365-380M
Q4 2021 revenue $84.7M (+104% YoY); net loss $(31.2)M vs $(5.2)M loss in Q4 2020.
Hims & Hers appoints new CFO Oluyemi Okupe, adds Dr. Patrick Carroll to board
Appointed Oluyemi Okupe as CFO effective Jan 24, 2022; previously CFO of Hipcamp, divisional CFO at Uber and Braintree.
On October 7, 2026, the Company's board of directors appointed Mr. Franklin as principal accounting officer of the Company, effective October 9, 2026, concurrently with the previously disclosed resignation of Irene Becklund as the Company's principal accounting officer.
On October 7, 2026, the Company's board of directors appointed Mr. Franklin as principal accounting officer of the Company, effective October 9, 2026, concurrently with the previously disclosed resignation of Irene Becklund as the Company's principal accounting officer.
On October 5, 2026, Jonathan M. Franklin commenced employment with Hims & Hers Health, Inc. (the “Company”) as chief accounting officer.
On July 13, 2026, Irene Becklund informed Hims & Hers Health, Inc. (the “Company”) of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026.
Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc. (the “Company”), announced her intention to transition into an advisory role with Hims & Hers in the coming months.
On November 15, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Deb Autor, 57, to fill the newly created vacancy, effective immediately.
On April 24, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from ten to eleven directors and appointed Anja Manuel, 49, to fill the newly created vacancy, effective immediately.
On March 30, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Christopher Payne, 55, to fill the newly created vacancy, effective March 30, 2024.
appointed Christiane Pendarvis, 52, to fill the newly created vacancy, effective February 16, 2023.
Irene Becklund, the Company’s controller, who is serving as interim principal financial officer and principal accounting officer as disclosed in the Company’s Current Report on Form 8-K filed on November 18, 2021, will continue as the Company’s principal accounting officer but will cease serving as interim principal financial officer upon the effectiveness of Mr. Okupe’s appointment.
On January 18, 2022, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) appointed Oluyemi Okupe as chief financial officer and principal financial officer of the Company, effective January 24, 2022.
appointed Dr. Patrick Carroll, M.D., 63
Max materiality 0.85 · Median 0.65 · Most common event earnings